Fund Holdings — ARCH Venture Management, LLC

Total Portfolio Value:
$1.61B
Total Bought:
$617.40M
Total Sold:
$9.68M
Net Transaction:
+$607.72M
Notable People:
Robert Taylor Nelsen
Securities
▲▼
SharesValue
Q2 2026
▲▼
Q3 2026
▲▼
Change
▲▼
Q2 2026
▲▼
Q3 2026
▲▼
Weight (%)
▲▼
Change
▲▼
Kardigan Inc015,042,036+15,042,036$0$221.87M13.75%+$221.87M
Parabilis Medicines Inc6,412,7806,412,7800$175.52M$207.07M12.83%+$31.55M
Vir Biotechnology, Inc.(VIR)12,694,16312,694,1630$129.35M$141.92M8.80%+$12.57M
Sana Biotechnology Inc045,860,681+45,860,681$0$133.68M8.29%+$133.68M
Seaport Therapeutics Inc6,294,9516,294,9510$136.60M$126.97M7.87%-$9.63M
Rapport Therapeutics, Inc.(RAPP)3,728,7383,728,7380$155.38M$125.29M7.77%-$30.09M
Scholar Rock Holding Corporation(SRRK)02,345,711+2,345,711$0$113.34M7.03%+$113.34M
Maze Therapeutics, Inc.(MAZE)4,120,0534,120,0530$122.98M$111.98M6.94%-$11.00M
Beam Therapeutics Inc.(BEAM)4,540,1324,540,1320$155.77M$111.01M6.88%-$44.77M
Erasca, Inc.(ERAS)7,091,5577,091,5570$129.92M$103.96M6.44%-$25.96M
908 Devices Inc05,725,045+5,725,045$0$70.65M4.38%+$70.65M
Prime Medicine, Inc.(PRME)018,486,894+18,486,894$0$56.48M3.50%+$56.48M
Lyell Immunopharma Inc3,247,1623,247,1620$45.53M$31.79M1.97%-$13.74M
Generate Biomedicines, Inc.(GENB)1,944,4261,944,4260$32.80M$29.21M1.81%-$3.60M
Neumora Therapeutics Inc.033,847,838+33,847,838$0$20.18M1.25%+$20.18M
Boundless Bio Inc2,694,0952,694,0950$6.74M$6.76M0.42%+$26.9K
Gossamer Bio Inc0100,698+100,698$0$1.19M0.07%+$1.19M
10x Genomics, Inc.CL A(TXG)217,8340-217,834$8.35M$0—-$8.35M
Gossamer Bio, Inc.(GOSS)8,055,9160-8,055,916$1.33M$0—-$1.33M
Page 1 of 1
ARCH Venture Management, LLC — 13F Holdings — Q3 2026 | TickerTrail